Jingnan Xue

Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers

Jinzhu Mao, Dongxu Wang, Junyu Long et al. · Journal for ImmunoTherapy of Cancer · 2021 · 249 citations · Full text

Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients

Xu Yang, Bowen Chen, Yanyu Wang et al. · Hepatology International · 2023 · 54 citations · Full text

Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer

Chengpei Zhu, Jingnan Xue, Yunchao Wang et al. · Frontiers in Immunology · 2023 · 37 citations · Full text

Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma

Xu Yang, Baofeng Lian, Nan Zhang et al. · BMC Medicine · 2024 · 37 citations · Full text

Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study

Chengpei Zhu, Hu Li, Xiaobo Yang et al. · Cancer Immunology Immunotherapy · 2023 · 32 citations · Full text